Advanced

Evaluation of insulin degludec as baseline insulin therapy in children and adolescents with type 1 diabetes

Sellbom, Malin and Nilsson, Charlotta LU (2021) In Practical Diabetes 38(2). p.13-19
Abstract

The incidence of type 1 diabetes in children is growing and optimal treatment is needed to prevent or delay complications. Insulin degludec is a new basal insulin with ultra-long effect. However, there are few published studies in children and adolescents. The first aim was to compare HbA1c levels in children and adolescents who received degludec from onset, to age/gender matched controls with other basal insulins. The second aim was to investigate HbA1c and total basal insulin dose, in patients who switched to insulin degludec from another basal insulin. Patients (n=251, 0–21 years) with type 1 diabetes, at Helsingborg Hospital, were divided into groups depending on insulin treatment. Data regarding basal insulin... (More)

The incidence of type 1 diabetes in children is growing and optimal treatment is needed to prevent or delay complications. Insulin degludec is a new basal insulin with ultra-long effect. However, there are few published studies in children and adolescents. The first aim was to compare HbA1c levels in children and adolescents who received degludec from onset, to age/gender matched controls with other basal insulins. The second aim was to investigate HbA1c and total basal insulin dose, in patients who switched to insulin degludec from another basal insulin. Patients (n=251, 0–21 years) with type 1 diabetes, at Helsingborg Hospital, were divided into groups depending on insulin treatment. Data regarding basal insulin and HbA1c values were collected from medical records retrospectively. No significant differences in HbA1c levels were found between patients receiving degludec compared to age/gender matched controls (n=22) up to 12 months from onset. In patients who switched to degludec with HbA1c ≥70mmol/mol (n=38), median HbA1c levels decreased from 75 (70–130) to 74 (39–99; p=0.0143) after three months and to 70.5 (55–108; p=0.0290) after six months. For patients who switched from detemir to degludec (n=54) median daily basal insulin dosage reduced from 23.5 units to 22 units after six months treatment with degludec (p=0.0001). The same significance was not found for glargine. In our study, degludec has shown to be as effective in lowering HbA1c levels as other basal insulins in children and adolescents with type 1 diabetes. Degludec might be especially useful for patients with a poor metabolic control. However, further long-term studies are needed.

(Less)
Please use this url to cite or link to this publication:
author
and
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
adolescents, children, HbA, insulin degludec, type 1 diabetes
in
Practical Diabetes
volume
38
issue
2
pages
7 pages
publisher
Wiley
external identifiers
  • scopus:85104068180
ISSN
2047-2897
DOI
10.1002/pdi.2327
language
English
LU publication?
yes
id
0679280a-86b7-4b87-a702-bfcd458b0a31
date added to LUP
2021-04-21 07:27:33
date last changed
2021-04-21 07:27:33
@article{0679280a-86b7-4b87-a702-bfcd458b0a31,
  abstract     = {<p>The incidence of type 1 diabetes in children is growing and optimal treatment is needed to prevent or delay complications. Insulin degludec is a new basal insulin with ultra-long effect. However, there are few published studies in children and adolescents. The first aim was to compare HbA<sub>1c</sub> levels in children and adolescents who received degludec from onset, to age/gender matched controls with other basal insulins. The second aim was to investigate HbA<sub>1c</sub> and total basal insulin dose, in patients who switched to insulin degludec from another basal insulin. Patients (n=251, 0–21 years) with type 1 diabetes, at Helsingborg Hospital, were divided into groups depending on insulin treatment. Data regarding basal insulin and HbA<sub>1c</sub> values were collected from medical records retrospectively. No significant differences in HbA<sub>1c</sub> levels were found between patients receiving degludec compared to age/gender matched controls (n=22) up to 12 months from onset. In patients who switched to degludec with HbA<sub>1c</sub> ≥70mmol/mol (n=38), median HbA<sub>1c</sub> levels decreased from 75 (70–130) to 74 (39–99; p=0.0143) after three months and to 70.5 (55–108; p=0.0290) after six months. For patients who switched from detemir to degludec (n=54) median daily basal insulin dosage reduced from 23.5 units to 22 units after six months treatment with degludec (p=0.0001). The same significance was not found for glargine. In our study, degludec has shown to be as effective in lowering HbA<sub>1c</sub> levels as other basal insulins in children and adolescents with type 1 diabetes. Degludec might be especially useful for patients with a poor metabolic control. However, further long-term studies are needed.</p>},
  author       = {Sellbom, Malin and Nilsson, Charlotta},
  issn         = {2047-2897},
  language     = {eng},
  number       = {2},
  pages        = {13--19},
  publisher    = {Wiley},
  series       = {Practical Diabetes},
  title        = {Evaluation of insulin degludec as baseline insulin therapy in children and adolescents with type 1 diabetes},
  url          = {http://dx.doi.org/10.1002/pdi.2327},
  doi          = {10.1002/pdi.2327},
  volume       = {38},
  year         = {2021},
}